Italia markets closed

Basilea Pharmaceutica AG (0QNA.L)

LSE - LSE Prezzo differito. Valuta in CHF.
Aggiungi a watchlist
38,60+0,05 (+0,13%)
Alla chiusura: 03:59PM BST
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    Basilea announces positive results of phase 3 ERADICATE study with ceftobiprole in Staphylococcus aureus bacteremia (SAB)

    Ceftobiprole met primary and secondary efficacy endpoints Basilea plans to submit a New Drug Application (NDA) in the U.S. around year end 2022 Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland, June 28, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today positive topline results for the phase 3 ERADICATE study, evaluating ceftobiprole in the treatment of adult patients with bacterial bloodstream infections caused by Staphylococcu

  • GlobeNewswire

    Basilea reports progress on the implementation of its strategy to focus on anti-infectives

    ERADICATE phase 3 study exploring ceftobiprole for the treatment of patients with Staphylococcus aureus bacteremia (SAB) expected to report results shortlySeparate transactions for TTK/PLK1 inhibitor (BAL0891) and preclinical oncology projects expected to be concluded in H2 2022 No expansion of ongoing lisavanbulin clinical studies; exploring partnering opportunitiesDerazantinib rights to be transferred back to Merck & Co. by the end of 2022No material expenses related to oncology activities bey

  • GlobeNewswire

    Basilea announces approval for additional formulation of antifungal Cresemba® (isavuconazole) in China

    Chinese National Medical Products Administration (NMPA) granted Drug Approval License to Basilea’s license partner, Pfizer Inc.Intravenous use of Cresemba approved for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis following previous approval of oral dosage form Basel/Allschwil, Switzerland, June 24, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today that its license partner, Pfizer Inc. (NYSE: PFE, “P